| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ginkgetin — a naturally occurring biflavonoid, specifically a dimethylated derivative of amentoflavone, found in Ginkgo biloba and several other plants. It is chemically and pharmacologically distinct from generic Ginkgo biloba extract, EGb 761, ginkgolides, bilobalide, and ginkgolic acids. Ginkgetin has predominantly preclinical anticancer evidence, with reported effects on ferroptosis, apoptosis, cell-cycle arrest, proliferation, invasion, angiogenesis, and chemotherapy sensitivity. Major signaling systems reported to be modulated include NRF2/HO-1, JAK/STAT, PI3K/AKT/GSK-3β, MAPK, Wnt/β-catenin, and TFEB-associated ferroptotic signaling. It should be treated as an isolated natural-product constituent rather than as evidence for the pharmacological effects of ordinary Ginkgo supplementation. Ginkgetin — a naturally occurring biflavonoid, specifically a 3′→8″-linked biflavone and dimethylated derivative of amentoflavone, with the synonym 7,4′-dimethylamentoflavone. It is a small-molecule plant polyphenol rather than a Ginkgo extract and is commonly abbreviated GK. Ginkgetin occurs in Ginkgo biloba leaves and several other plant species. It is chemically and pharmacologically distinct from generic Ginkgo biloba extract, EGb 761, ginkgolides, bilobalide, and ginkgolic acids. Current evidence is predominantly preclinical and supports treating Ginkgetin as a separate isolated natural-product constituent rather than extrapolating its effects to ordinary Ginkgo supplementation. Primary mechanisms (ranked):
Bioavailability / PK relevance: Ginkgetin is highly lipophilic and poorly water-soluble, creating an important oral-delivery limitation. Human pharmacokinetic data for isolated Ginkgetin are essentially absent, and no validated human anticancer plasma target or therapeutic dose has been established. Experimental formulation work, including nanomicelles, is being investigated specifically to improve its systemic exposure. Ginkgetin is also a potent in-vitro inhibitor of UGT1A1, creating a potential drug-interaction concern if pharmacologically relevant systemic concentrations can be achieved. In-vitro vs systemic exposure relevance: Most anticancer studies use isolated Ginkgetin at micromolar concentrations, commonly over prolonged exposures. These concentrations cannot presently be assumed achievable through oral Ginkgo products or conventional Ginkgetin administration because human Cmax data are unavailable and oral bioavailability is poorly characterized. Thus, direct translation of micromolar cell-culture effects to dietary or supplemental Ginkgo exposure is weak. Clinical evidence status: Preclinical only. Evidence includes cancer-cell studies and multiple mouse xenograft or metastasis models, including lung, breast, prostate, medulloblastoma, and cervical-cancer systems. No established human anticancer trials, approved anticancer indication, validated clinical dose, or demonstrated human therapeutic efficacy was identified. FDA substance registration provides a chemical identifier but does not constitute regulatory approval. Ginkgetin Cancer-Relevant Mechanisms
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| GRP78 (Pgp, BiP or ERp72) is a central regulator of endoplasmic reticulum (ER) function due to its roles in protein folding and assembly, targeting misfolded protein for degradation, ER Ca(2+)-binding and controlling the activation of trans-membrane ER stress sensors. -GRP78 protein, a marker for endoplasmic reticulum stress -GRP78’s role as a master regulator of the unfolded protein response (UPR) and cellular stress responses The association of P-gp and inhibition of cell death in cancerous cells has also been reported in several studies including in hepatocellular, colorectal, prostate cancer, and gastric cancer. Although counterintuitive due to its prominent role in cancer resistance, P-gp has been linked to favorable prognosis. ERp72 can promote cancer cell proliferation, migration, and invasion by regulating various signaling pathways, including the PI3K/AKT and MAPK/ERK pathways. Additionally, ERp72 can also inhibit apoptosis (programmed cell death) in cancer cells, which can contribute to tumor progression. Overexpressed in: Breast, lung colorectal, prostrate, ovarian, pancreatic. -GRP78 is frequently upregulated in a variety of solid tumors and hematological malignancies. -Overexpression of GRP78 in cancer cells is often regarded as a marker of increased ER stress due to the reduced oxygen and nutrient supply typically encountered in the tumor microenvironment. -Elevated GRP78 levels can contribute to tumor cell survival by enhancing the adaptive UPR, allowing cancer cells to cope with therapeutic and metabolic stress. |
| 7265- | Gink, | Ginkgetin targets GRP78 to induce dual pathways of ER stress and immune activation in osteosarcoma |
| - | vitro+vivo, | OS, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:437 Target#:356 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid